Castle Biosciences, Inc. Sustainability Profile
Castle Biosciences, Inc., a leading biotechnology company headquartered in the United States, specialises in innovative diagnostic solutions for skin cancer and other complex diseases. Founded in 2007, the company has made significant strides in the field of personalised medicine, particularly with its flagship products, the DecisionDx® tests, which provide critical insights for melanoma and non-melanoma skin cancers. With a strong presence across the US and expanding operations internationally, Castle Biosciences is recognised for its commitment to improving patient outcomes through advanced genomic testing. The company has achieved notable milestones, including the successful launch of its proprietary tests that help clinicians make informed treatment decisions. As a pioneer in the dermatological diagnostics industry, Castle Biosciences continues to set the standard for precision medicine, solidifying its position as a trusted partner in oncology care.
DitchCarbon Score
How does Castle Biosciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Castle Biosciences, Inc.'s score of 27 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Castle Biosciences, Inc.'s reported carbon emissions
In 2022, Castle Biosciences, Inc. reported total carbon emissions of approximately 755,080 kg CO2e, which includes 24,130 kg CO2e from Scope 1 emissions and 730,950 kg CO2e from Scope 2 emissions (market-based). The company has not disclosed any Scope 3 emissions data. Castle Biosciences has not set specific reduction targets or initiatives as part of its climate commitments, nor does it participate in initiatives such as the Science Based Targets initiative (SBTi). The absence of reduction targets indicates a potential area for future development in their sustainability strategy. As a company headquartered in the US, Castle Biosciences is positioned within an industry increasingly focused on climate accountability and emissions reduction. However, without specific commitments or targets, the company may face challenges in aligning with broader industry standards and expectations for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 24,130 |
| Scope 2 | 730,950 |
| Scope 3 | - |
How Carbon Intensive is Castle Biosciences, Inc.'s Industry?
How Carbon Intensive is Castle Biosciences, Inc.'s Location?
Castle Biosciences, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Castle Biosciences, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
